Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
-0.67% $1.490
America/New_York / 25 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 43.17 mill |
EPS: | -0.240 |
P/E: | -6.21 |
Earnings Date: | May 08, 2024 |
SharesOutstanding: | 28.97 mill |
Avg Daily Volume: | 0.0232 mill |
RATING 2024-04-25 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Strong Sell | |
Return On Asset: | Strong Sell | |
DE: | Neutral | |
P/E: | Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt | n/a | n/a | n/a | n/a | n/a |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -6.21 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-1.06x |
Company: PE -6.21 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 1.366 - 1.614 ( +/- 8.32%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-11 | Lucy Patrick K. | Buy | 13 125 | Stock Option |
2024-04-11 | Tarnok Michael P. | Sell | 13 125 | Stock Option |
2024-04-11 | Hazelton Joseph P | Buy | 20 000 | Stock Option |
2024-03-13 | Hazelton Joseph P | Buy | 41 720 | Common Stock |
2024-03-13 | Emalfarb Mark A | Buy | 124 454 | Common Stock |
INSIDER POWER |
---|
81.69 |
Last 99 transactions |
Buy: 3 507 936 | Sell: 1 014 811 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $1.490 (-0.67% ) |
Volume | 0.0032 mill |
Avg. Vol. | 0.0232 mill |
% of Avg. Vol | 13.84 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; and collaboration with Syngene International Limited. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.